Literature DB >> 15939748

Adoptive immunotherapy of feline immunodeficiency virus with autologous ex vivo-stimulated lymphoid cells modulates virus and T-cell subsets in blood.

J Norman Flynn1, Mauro Pistello, Patrizia Isola, Lucia Zaccaro, Barbara Del Santo, Enrica Ricci, Donatella Matteucci, Mauro Bendinelli.   

Abstract

The potential of immunotherapy with autologous virus-specific T cells to affect the course of feline immunodeficiency virus (FIV) infection was explored in a group of specific-pathogen-free cats infected with FIV a minimum of 10 months earlier. Popliteal lymph node cells were stimulated by cocultivation with UV-inactivated autologous fibroblasts infected with recombinant vaccinia viruses expressing either FIV gag or env gene products, followed by expansion in interleukin-2. One or two infusions of both Gag- and Env-stimulated cells resulted in a slow increase in FIV-specific gamma interferon-secreting T cells in the circulation of cats. In the same animals, viral set points fluctuated widely during the first 2 to 3 weeks after adoptive transfer and then returned to pretreatment levels. The preexisting viral quasispecies was also found to be modulated, whereas no novel viral variants were detected. Circulating CD4(+) counts underwent a dramatic decline early after treatment. CD4/CD8 ratios remained instead essentially unchanged and eventually improved in some animals. In contrast, a single infusion of Gag-stimulated cells alone produced no apparent modulations of infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15939748      PMCID: PMC1151978          DOI: 10.1128/CDLI.12.6.736-745.2005

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  44 in total

1.  Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.

Authors:  U Dittmer; B Race; K J Hasenkrug
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Vaccination with inactivated virus but not viral DNA reduces virus load following challenge with a heterologous and virulent isolate of feline immunodeficiency virus.

Authors:  M J Hosie; T Dunsford; D Klein; B J Willett; C Cannon; R Osborne; J Macdonald; N Spibey; N Mackay; O Jarrett; J C Neil
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

3.  Roles of target cells and virus-specific cellular immunity in primary simian immunodeficiency virus infection.

Authors:  Roland R Regoes; Rustom Antia; David A Garber; Guido Silvestri; Mark B Feinberg; Silvija I Staprans
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

4.  Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.

Authors:  D J Moss; A B Rickinson; J H Pope
Journal:  Int J Cancer       Date:  1978-12       Impact factor: 7.396

5.  Virus-specific cytotoxic T-lymphocyte responses select for amino-acid variation in simian immunodeficiency virus Env and Nef.

Authors:  D T Evans; D H O'Connor; P Jing; J L Dzuris; J Sidney; J da Silva; T M Allen; H Horton; J E Venham; R A Rudersdorf; T Vogel; C D Pauza; R E Bontrop; R DeMars; A Sette; A L Hughes; D I Watkins
Journal:  Nat Med       Date:  1999-11       Impact factor: 53.440

6.  Direct visualization of HIV-1-specific cytotoxic T lymphocytes during primary infection.

Authors:  J D Wilson; G S Ogg; R L Allen; C Davis; S Shaunak; J Downie; W Dyer; C Workman; S Sullivan; A J McMichael; S L Rowland-Jones
Journal:  AIDS       Date:  2000-02-18       Impact factor: 4.177

7.  Hierarchical targeting of subtype C human immunodeficiency virus type 1 proteins by CD8+ T cells: correlation with viral load.

Authors:  Agatha Masemola; Tumelo Mashishi; Greg Khoury; Phineas Mohube; Pauline Mokgotho; Efthyia Vardas; Mark Colvin; Lynn Zijenah; David Katzenstein; Rosemary Musonda; Susan Allen; Newton Kumwenda; Taha Taha; Glenda Gray; James McIntyre; Salim Abdool Karim; Haynes W Sheppard; Clive M Gray
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  Peptide mapping of feline immunodeficiency virus by IFN-gamma ELISPOT.

Authors:  Gregg A Dean; Alora LaVoy; Mary Jo Burkhard
Journal:  Vet Immunol Immunopathol       Date:  2004-07       Impact factor: 2.046

Review 9.  Transmission and immunopathogenesis of FIV in cats as a model for HIV.

Authors:  Mary Jo Burkhard; Gregg A Dean
Journal:  Curr HIV Res       Date:  2003-01       Impact factor: 1.581

10.  Development of antibodies to feline IFN-gamma as tools to elucidate the cellular immune responses to FeLV.

Authors:  Elizabeth M Graham; Oswald Jarrett; J Norman Flynn
Journal:  J Immunol Methods       Date:  2003-08       Impact factor: 2.303

View more
  3 in total

1.  AIDS vaccination studies with an ex vivo feline immunodeficiency virus model: analysis of the accessory ORF-A protein and DNA as protective immunogens.

Authors:  Mauro Pistello; Francesca Bonci; J Norman Flynn; Paola Mazzetti; Patrizia Isola; Elisa Zabogli; Valentina Camerini; Donatella Matteucci; Giulia Freer; Paolo Pelosi; Mauro Bendinelli
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

2.  Env-expressing autologous T lymphocytes induce neutralizing antibody and afford marked protection against feline immunodeficiency virus.

Authors:  Mauro Pistello; Francesca Bonci; Elisa Zabogli; Francesca Conti; Giulia Freer; Fabrizio Maggi; Mario Stevenson; Mauro Bendinelli
Journal:  J Virol       Date:  2010-02-03       Impact factor: 5.103

3.  Failure of low-dose recombinant human IL-2 to support the survival of virus-specific CTL clones infused into severe combined immunodeficient foals: lack of correlation between in vitro activity and in vivo efficacy.

Authors:  Robert H Mealey; Matt H Littke; Steven R Leib; William C Davis; Travis C McGuire
Journal:  Vet Immunol Immunopathol       Date:  2007-07-25       Impact factor: 2.046

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.